P. Keegan

发表

FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD‐L1

L. Fashoyin-Aje, Martha Donoghue, Huanyu Chen, 2018, The oncologist.

A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics: A Review

L. Howie, K. Goldberg, P. Keegan, 2018, JAMA oncology.

Study design in the evaluation of breast cancer imaging technologies.

R. F. Wagner, J. Gohagan, W. M. Sacks, 2000, Academic radiology.

Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer

Lawrence H. Schwartz, Donald A. Berry, Janis M. Taube, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.

Richard Pazdur, P. Keegan, R. Pazdur, 2007, The oncologist.

U.S. Food and Drug Administration Approval: Ofatumumab for the Treatment of Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine and Alemtuzumab

Justin C. Earp, P. Keegan, R. Pazdur, 2010, Clinical Cancer Research.

FDA Oncology Center of Excellence Project Renewal: Engaging the Oncology Community to Update Product Labeling for Older Oncology Drugs

G. Demetri, L. Burke, Martha Donoghue, 2020, Clinical Cancer Research.

FDA Approval Summary: Trabectedin for Unresectable or Metastatic Liposarcoma or Leiomyosarcoma Following an Anthracycline-Containing Regimen

Huanyu Chen, K. He, K. Goldberg, 2017, Clinical Cancer Research.

FDA Approval Summary: TAS-102

K. He, P. Keegan, R. Pazdur, 2017, Clinical Cancer Research.

Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials: Symptomatic Adverse Events, Physical Function, and Disease-Related Symptoms

Martha Donoghue, P. Keegan, R. Pazdur, 2016, Clinical Cancer Research.

FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine–Refractory Differentiated Thyroid Cancer

K. He, P. Keegan, R. Pazdur, 2015, Clinical Cancer Research.

FDA Approval Summary: Ramucirumab for Gastric Cancer

Huanyu Chen, K. He, P. Keegan, 2015, Clinical Cancer Research.

Eribulin Mesylate for the Treatment of Patients with Refractory Metastatic Breast Cancer: Use of a “Physician's Choice” Control Arm in a Randomized Approval Trial

Martha Donoghue, K. He, P. Keegan, 2012, Clinical Cancer Research.

FDA drug approval summary: panitumumab (Vectibix).

P. Keegan, R. Pazdur, Martin H. Cohen, 2007, The oncologist.

Continuing Reassessment of the Risks of Erythropoiesis-Stimulating Agents in Patients with Cancer

P. Keegan, R. Pazdur, M. Rothmann, 2008, Clinical Cancer Research.

FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors

P. Keegan, R. Pazdur, S. Lemery, 2019, Clinical Cancer Research.

Development and regulation of monoclonal antibody products: Challenges and opportunities

M. Frazier-Jessen, P. Keegan, W. J. Wu, 2005, Cancer and Metastasis Reviews.

FDA Approval Summary: Accelerated Approval of Pembrolizumab for Second-Line Treatment of Metastatic Melanoma

K. He, P. Keegan, R. Pazdur, 2017, Clinical Cancer Research.

FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancer.

P. Keegan, R. Pazdur, Martin H. Cohen, 2009, The oncologist.

U.S. Food and Drug Administration Approval: Panitumumab for Epidermal Growth Factor Receptor–Expressing Metastatic Colorectal Carcinoma with Progression Following Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Containing Chemotherapy Regimens

P. Keegan, R. Pazdur, Hong Zhao, 2008, Clinical Cancer Research.

Evaluation of Blinded Independent Central Review of Tumor Progression in Oncology Clinical Trials: A Meta-analysis

Huanyu Chen, P. Keegan, R. Pazdur, 2013, Therapeutic innovation & regulatory science.

Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial.

Qi Li, P. Keegan, Jianxing He, 2022, Cancer cell.

FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma.

P. Keegan, R. Pazdur, Martin H. Cohen, 2010, The oncologist.

Accelerated approval of oncology products: the food and drug administration experience.

P. Keegan, R. Pazdur, R. Justice, 2011, Journal of the National Cancer Institute.

Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective.

P. Keegan, B. Booth, B. Furmanski, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic Non-Small Cell Lung Cancer Following Disease Progression On or After Platinum-Based Chemotherapy.

P. Keegan, R. Pazdur, G. Blumenthal, 2015, The oncologist.

Regulatory Issues : FDA U . S . Food and Drug Administration Approval Summary : Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed

P. Keegan, R. Pazdur, G. Blumenthal, 2016 .

FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma.

Martha Donoghue, P. Keegan, R. Pazdur, 2020, The oncologist.

The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention.

P. Keegan, R. Pazdur, R. Justice, 2011, The New England journal of medicine.

FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).

P. Keegan, R. Pazdur, Martin H. Cohen, 2007, The oncologist.

Oncology clinical trials

P. Müller, T. Lai, G. Rosner, 2013 .

FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum‐Containing Chemotherapy

K. Goldberg, P. Keegan, Amy McKee, 2017, The oncologist.

FDA Approval Summary: Pembrolizumab for the Treatment of Patients with Unresectable or Metastatic Melanoma

Huanyu Chen, P. Keegan, R. Pazdur, 2017, Clinical Cancer Research.

US Food and Drug Administration approval overview in metastatic breast cancer.

P. Keegan, R. Pazdur, P. Cortazar, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies

G. Giaccone, S. Bates, M. Atkins, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

FDA analyses of survival in older adults with metastatic non-small cell lung cancer in controlled trials of PD-1/PD-L1 blocking antibodies.

P. Keegan, R. Pazdur, G. Blumenthal, 2018, Seminars in oncology.

Exposure-response (E-R) and case-control analyses of ramucirumab leading to recommendation for dosing optimization in patients with gastric cancer.

L. Fashoyin-Aje, P. Keegan, Hong Zhao, 2015 .

doxorubicin, cyclophosphamide) chemotherapy breast cancer patients treated with FLAC (5-fluorouracil, leucovorin, granulocyte-macrophage colony-stimulating factor in advanced A phase I study of sequential versus concurrent interleukin-3 and

A. Tolcher, D. Venzon, P. Keegan, 2011 .

A phase I study of sequential versus concurrent interleukin-3 and granulocyte-macrophage colony-stimulating factor in advanced breast cancer patients treated with FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy

A. Tolcher, D. Venzon, P. Keegan, 1995 .

A. Tolcher, D. Venzon, P. Keegan, 1995, Blood.

Title: FDA Approval Summary: Pembrolizumab for the treatment of microsatellite instability- high solid tumors Running Title: FDA Approval Summary: Pembrolizumab for MSI-H solid tumors

P. Keegan, R. Pazdur, S. Lemery, 2019 .

FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia.

P. Keegan, R. Pazdur, J. Summers, 2008, The oncologist.

Early clinical trials of chemopreventive and biologic agents: Designs, populations, and endpoints.

P. Keegan, B. E. Loughman, 2001, Urology.

Cardiotoxicity associated with paclitaxel/trastuzumab combination therapy.

P. Keegan, S. Jerian, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FDA Approval Summary: Entrectinib for the Treatment of NTRK gene Fusion Solid Tumors

Martha Donoghue, P. Keegan, R. Pazdur, 2020, Clinical Cancer Research.

FDA Approval Summary: Sonidegib for Locally Advanced Basal Cell Carcinoma

Huanyu Chen, P. Keegan, R. Pazdur, 2017, Clinical Cancer Research.

Prospective, randomized trial of 5-fluorouracil, leucovorin, doxorubicin, and cyclophosphamide chemotherapy in combination with the interleukin-3/granulocyte-macrophage colony-stimulating factor (GM-CSF) fusion protein (PIXY321) versus GM-CSF in patients with advanced breast cancer.

A. Tolcher, D. Venzon, P. Keegan, 1996, Blood.

Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial

Hung-Ming Wang, Ruifeng Xu, Jianji Pan, 2021, Nature Medicine.

Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)

Ying Cheng, P. Keegan, Baolan Li, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Food and Drug Administration Approval : Ofatumumab the Treatment of Patients with Chronic Lymphocytic R kemia Refractory to Fludarabine and Alemtuzumab

Justin C. Earp, P. Keegan, R. Pazdur, 2010 .

U.S. Food and Drug Administration Approval: Vismodegib for Recurrent, Locally Advanced, or Metastatic Basal Cell Carcinoma

P. Keegan, R. Pazdur, A. Russell, 2013, Clinical Cancer Research.

A phase II study of piritrexim in patients with advanced squamous head and neck cancer

A. Huang, P. Keegan, S. Jones, 1992, Cancer.

FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements.

Huanyu Chen, P. Keegan, R. Pazdur, 2014, The oncologist.

FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy

Gideon Blumenthal, Richard Pazdur, P. Keegan, 2016, The oncologist.

Systematic Review of PD‐1/PD‐L1 Inhibitors in Oncology: From Personalized Medicine to Public Health

L. Fashoyin-Aje, Janaki Veeraraghavan, K. Goldberg, 2021, The oncologist.

Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy

R. Doebele, P. Keegan, R. Pazdur, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non–Small Cell Lung Cancer Following Crizotinib

Huanyu Chen, P. Keegan, Amy McKee, 2016, Clinical Cancer Research.

FDA Approval: Ceritinib for the Treatment of Metastatic Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer

Sean Khozin, Ping Zhao, Richard Pazdur, 2015, Clinical Cancer Research.

FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme.

P. Keegan, R. Pazdur, Martin H. Cohen, 2009, The oncologist.

Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST version 1.1-defined disease progression in clinical trials.

P. Keegan, R. Pazdur, G. Blumenthal, 2017, Seminars in oncology.

Clinician Perspectives on Current Issues in Lung Cancer Drug Development

P. Jänne, R. Govindan, R. Herbst, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1

P. Keegan, R. Pazdur, G. Blumenthal, 2016, The oncologist.

Benefit-Risk Summary of Nivolumab for Patients With Metastatic Squamous Cell Lung Cancer After Platinum-Based Chemotherapy: A Report From the US Food and Drug Administration.

S. Khozin, P. Keegan, R. Pazdur, 2016, JAMA oncology.

FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non‐Small Cell Lung Cancer: First‐Line Therapy and Beyond

K. Goldberg, P. Keegan, Amy McKee, 2017, The oncologist.

FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non‐Small Cell Lung Cancers Harboring BRAF V600E Mutations

Reena Philip, K. Goldberg, P. Keegan, 2018, The oncologist.

Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non-Small Cell Lung Cancer.

P. Keegan, R. Pazdur, G. Blumenthal, 2019, JAMA oncology.

U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.

S. Khozin, P. Keegan, R. Pazdur, 2014, The oncologist.

Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03

F. Zhou, P. Keegan, Jiyan Liu, 2021, Clinical Cancer Research.

Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis

P. Keegan, R. Pazdur, R. Sridhara, 2020, Journal for ImmunoTherapy of Cancer.

Overall response rate (ORR) as a potential surrogate for progression-free survival (PFS): A meta-analysis of metastatic non-small cell lung cancer (mNSCLC) trials submitted to the U.S. Food and Drug Administration (FDA).

S. Khozin, P. Keegan, R. Pazdur, 2014 .

FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer.

P. Keegan, R. Pazdur, Martin H. Cohen, 2007, The oncologist.

First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication.

P. Keegan, R. Pazdur, S. Lemery, 2017, The New England journal of medicine.

Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy

K. Goldberg, P. Keegan, R. Pazdur, 2020, Current Oncology Reports.

FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation–Positive Non–Small Cell Lung Cancer

P. Keegan, R. Pazdur, G. Blumenthal, 2016, Clinical Cancer Research.

Osimertinib for the Treatment of Metastatic EGFR T790M Mutation–Positive Non–Small Cell Lung Cancer

S. Khozin, P. Keegan, R. Pazdur, 2016, Clinical Cancer Research.

Expansion Cohorts in First-in-Human Solid Tumor Oncology Trials

P. Keegan, R. Pazdur, Geoffrey Kim, 2015, Clinical Cancer Research.

Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non–Small Cell Lung Cancer Trials: A Meta-analysis

S. Khozin, K. Goldberg, P. Keegan, 2017, JAMA oncology.

Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses.

Sean Khozin, Hui Zhang, Richard Pazdur, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

U.S. Food and Drug Administration Approval: peginterferon-alfa-2b for the adjuvant treatment of patients with melanoma.

P. Keegan, R. Pazdur, Martin H. Cohen, 2012, The oncologist.

Benefit‐Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib

Jiang Liu, K. Goldberg, P. Keegan, 2018, The oncologist.

Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response

Jiang Liu, P. Keegan, M. Chatterjee, 2017, Journal of Pharmacokinetics and Pharmacodynamics.

U.S. Food and drug administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia.

P. Keegan, R. Pazdur, A. Khandelwal, 2011, The oncologist.

Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration—Melanoma Research Alliance Public Workshop

D. Berry, J. Taube, K. Flaherty, 2020, Clinical Cancer Research.

FDA analysis of depth of response (DpR) and survival across 10 randomized controlled trials in patients with previously untreated unresectable or metastatic melanoma (UMM) by therapy type.

P. Keegan, R. Pazdur, R. Sridhara, 2019, Journal of Clinical Oncology.

U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab

P. Keegan, R. Pazdur, Hong Zhao, 2017, Clinical Cancer Research.

Evaluation of the potential for QT/QTc interval prolongation for therapeutic biotechnology products.

P. Keegan, Hong Zhao, B. Booth, 2014 .

Flat dose regimen of toripalimab based on model-informed drug development approach

P. Keegan, Qun Zhao, Yun-fei Lin, 2023, Frontiers in Pharmacology.

Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007.

P. Keegan, R. Pazdur, R. Justice, 2010, Journal of the National Cancer Institute.

The Combination of Exposure‐Response and Case‐Control Analyses in Regulatory Decision Making

C. Garnett, P. Keegan, J. Gobburu, 2013, Journal of clinical pharmacology.

Combination of exposure-response and case-control analyses in regulatory decision making.

C Garnett, J Gobburu, C. Garnett, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Accelerated approval of oncology products: a decade of experience.

Richard Pazdur, P. Keegan, R. Pazdur, 2004, Journal of the National Cancer Institute.

Approval : Alectinib for the Treatment of Metastatic ALK-Positive Non – Small Cell Lung Cancer Following

Huanyu Chen, P. Keegan, Amy McKee, 2016 .

Overview of Oncology and Hematology Drug Approvals at US Food and Drug Administration Between 2008 and 2016.

P. Keegan, R. Pazdur, R. Sridhara, 2018, Journal of the National Cancer Institute.

Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer.

Richard Pazdur, Huanyu Chen, P. Keegan, 2013, The oncologist.

FDA Approval Summary: Eribulin for Patients with Unresectable or Metastatic Liposarcoma Who Have Received a Prior Anthracycline-Containing Regimen

Lan Huang, P. Keegan, R. Pazdur, 2017, Clinical Cancer Research.

Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials—Response

Martha Donoghue, P. Keegan, R. Pazdur, 2016, Clinical Cancer Research.

Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective.

P. Keegan, B. Booth, B. Furmanski, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

FDA Benefit‐Risk Assessment of Osimertinib for the Treatment of Metastatic Non‐Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation

Reena Philip, Martha Donoghue, K. Goldberg, 2017, The oncologist.

An FDA Pooled Analysis of Patients with Melanoma Treated with an Anti-PD1 Antibody Beyond RECIST Progression

Huanyu Chen, K. Goldberg, P. Keegan, 2018, The Lancet. Oncology.

Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis.

Huanyu Chen, K. Goldberg, P. Keegan, 2018, The Lancet. Oncology.

Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy.

R. Doebele, P. Keegan, R. Pazdur, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy.

R. Doebele, P. Keegan, R. Pazdur, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Characterization of patients treated with a programmed cell death protein 1 inhibitor (anti-PD-1) past RECIST progression from a metastatic non-small cell lung cancer (mNSCLC) trial.

S. Khozin, P. Keegan, R. Pazdur, 2016 .

Racial composition in trials supporting the U.S. approval of anti-cancer new molecular entities (NMEs): 2011- 2016.

L. Fashoyin-Aje, P. Keegan, R. Pazdur, 2017 .

Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response

Manash S. Chatterjee, Jiang Liu, P. Keegan, 2017, Journal of Pharmacokinetics and Pharmacodynamics.

Exploratory responder analyses of greatest depth of response (DepOR) and survival in patients with metastatic non-small cell lung cancer (mNSCLC) treated with a targeted therapy or immunotherapy.

R. Doebele, P. Keegan, R. Pazdur, 2016 .

FDA Approval of Nivolumab for the First-Line Treatment of Patients with BRAFV600 Wild-Type Unresectable or Metastatic Melanoma

K. Goldberg, P. Keegan, Amy McKee, 2017, Clinical Cancer Research.

Pancreatic enzyme supplementation in cystic fibrosis.

P. Keegan, C. Hill, C. Rolles, 1993, Archives of disease in childhood.

Clinical outcome assessments in neuro-oncology: a regulatory perspective.

P. Keegan, P. Kluetz, Elektra J. Papadopoulos, 2016, Neuro-oncology practice.

Accelerated approval and oncology drug development timelines.

Richard Pazdur, Robert Justice, Rajeshwari Sridhara, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FDA's Approach to Regulating Biosimilars

Richard Pazdur, P. Keegan, Amy McKee, 2016, Clinical Cancer Research.

Phase I study of the anti-BTLA antibody icatolimab as a single agent or in combination with toripalimab in relapsed/refractory lymphomas.

P. Keegan, Jun Zhu, Jun Ma, 2022, Journal of Clinical Oncology.

Cancer Surveillance in Gorlin Syndrome and Rhabdoid Tumor Predisposition Syndrome

W. Foulkes, D. Evans, K. Nathanson, 2017, Clinical Cancer Research.

U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic Non-Small Cell Lung Cancer Following Disease Progression On or After Platinum-Based Chemotherapy.

P. Keegan, R. Pazdur, G. Blumenthal, 2015, The oncologist.

U.S. Food and Drug Administration Approval: Vismodegib for Recurrent, Locally Advanced, or Metastatic Basal Cell Carcinoma

P. Keegan, R. Pazdur, A. Russell, 2013, Clinical Cancer Research.

S. Khozin, P. Keegan, R. Pazdur, 2014, The oncologist.

FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation–Positive Non–Small Cell Lung Cancer